Experimental oncology
Clinical onco-hematology
Onco-hematology group is active in basic research, clinical research and routine patient care for acute leukemias, myelodisplasia and mieloproliferative disorders. One of the main goals is implementation of investigator-initiated clinical research. To this purpose, the infrastructures comprise a clinical care facility with ISO-9001 accreditation comprising all the requirements for care of patients, a bone marrow transplantation unit (JACIE certified) and a dedicated Day Hospital Unit.
Research activity
Onco-Hematology unit participates to several original, national and international clinical and traslational studies, at our Institute and within disease networks (NILG, GIMEMA, EORTC, REL, EBMT). The unit enroll patients in multicentric phase I-III trials aimed at evaluating the efficacy of new drugs and new treatment strategies. The group also contributed to set up the REL MDS and AML, web- based, registries, which are collecting multiple epidemiologic, clinical, biological and genetic data from patients followed at the regional haematologic centers.
In 2009 the unit started to collect biological samples from patients with acute leukemias and MDS in the OSR biobank. Since then the biobank provided samples both for molecular characterization for multicentric studies within the REL, GITMO and EBM, with new generation assays, and for several laboratories inIRCCS Ospedale San Raffaele thus supporting several important pre-clinical studies in the field of AML and gene therapy. This group went on with studies on WT1 monitoring to predict MRD persistence or recurrence after allogeneic transplantation and evaluating WT1 and NPM1 levels, as a quantitative marker of leukemic contamination, in autologous PBSC used for autotransplant after myeloablative chemotherapy. The unit has also particularly focused and distinguished in the intensive treatment of elderly (> 65-70 y) patients with AML and MDS, including autologous or allogeneic transplantation.
Shimoni A, Vago L, Bernardi M, Yerushalmi R, Peccatori J, Greco R, Shem-Tov N, Lo Russo A, Danylesko I, Apel A, Bonini C, Lupo Stanghellini MT, Nagler A, Ciceri F. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. Am J Hematol. 2017 Oct;92(10):1011-1019.
Della Porta MG, Jackson C, Alessandrino E, Rossi M, Bacigalupo A, Van Lint MT, Massimo Bernardi M, Bosi A, Allione B, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori A, Cerretti R, Grillo G, Molteni A, Pioltelli PE, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Leukemia 2017;31:449–2457.
Della Porta MG, Gall A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricala S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M. Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2016;34(30):3627-3637.
Bernardi M, Carrabba M, Messina C, Milani R, Sala E, Pavesi F, Gentner B, Peccatori J, Assanelli A, Marktel S, Corti C, Forcina A, Vago L, Ciceri F. Elderly patients > 65 years of age with acute myeloid leukemia and normal karyotype benefit from intensive therapeutic programs. Am J Hematol, 2016;91(6):E302-3.
Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A, Della Porta MG, Nichelatti M, Ravano E, Quaresmini G, Mariotti J, Caramazza D, Ubezio M, Guarco S, Gigli F, Greco R, Cairoli R, Morra E. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the “Rete Ematologica Lombarda”. Leukemia Research, 2016;42:21-27.
Brambati C, Galbiati S, Xue E, Toffalori C, Crucitti L, Greco R, Sala E, Crippa A, Chiesa L, Soriani N, Mazzi B, Tresoldi C, Lupo Stanghellini MT, Peccatori J, Carrabba MG, Bernardi M, Ferrari M, Lampasona V, Ciceri F, Vago L. Droplet digital PCR for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Haematologica 2016;101(4):e157-61.
Xue E, Tresoldi C, Sala E, Crippa A, Mazzi B, Greco R, Messina C, Carrabba MG, Lupo Stanghellini MT, Marktel S, Corti C, Peccatori J, Bernardi M, Ciceri F, Vago L. Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse. Bone Marrow Transplant 2016;51(3):466-9.
Messina C, Candoni A, Carrabba MG, Tresoldi C, Sala E, Tassara M, Crippa A, Peccatori J, Assanelli A, Gattillo S, Bellio L, Fanin R, Ciceri F, Bernardi M. Wilms’ tumor gene 1 transcript levels in leukapheresis of peripheral blood haematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(10):1586-91.
Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Bernasconi P, Bosi A, Cazzola M, Rambaldi A, on behalf of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic scoring System (IPSSR). Blood 2014;123(15):2333-42.
Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013 Jan 3;368(1):22-33.
